The use of recombinant human growth hormone to protect against muscle weakness in patients undergoing anterior cruciate ligament reconstruction: a pilot, randomized placebo-controlled trial
This is 40 times the standard subcutaneous dose, suggesting a wide safety margin
Twenty-four participants completed the 4-week assessment, and eleven completed the 12-week assessment
To address this, we have used a HEK293 cell-based system where GNE is either knocked down or the cells over-express mutant GNE recombinant protein
The rankings and reviews in this article represent the editorial opinion of the Protide Health publishing team and are not independent
Bieber, Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria., in J Biol Chem, vol